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Abstract
Background: Coverage decisions determining the benefit baskets of health systems have been increasingly relying on
evidence regarding patient benefit and costs. Relevant structures, methodologies, and processes have especially been
established for pharmaceuticals but approaches differ. The objective of this work was thus to identify institutions in a
broad range of European countries (n = 36) in charge of determining the value of pharmaceuticals for pricing and
reimbursement purposes and to map their decision-making process; to examine the different approaches and consider
national and supranational possibilities for best practice.
Methods: Institutions were identified through websites of international networks, ministries, and published literature.
Details on institutional practices were supplemented with information from institution websites and linked online sources.
Results: The type and extent of information available varied considerably across countries. Different types of public
regulatory bodies are involved in pharmaceutical coverage decisions, assuming a range of responsibilities. As a rule, the
assessment of scientific evidence is kept structurally separate from its appraisal. Recommendations on value are uniformly
issued by specific committees within or commissioned by responsible institutions; these institutions often also act as
decision-makers on reimbursement status and level or market price. While effectiveness and costs are important criteria in
all countries, the latter are often considered on a case-by-case basis. In all countries, manufacturer applications, including
relevant evidence, are used as one of the main sources of information for the assessment.
Conclusion: Transparency of evidence-based coverage decisions should be enhanced. International collaboration can
facilitate knowledge exchange, improve efficiency of information production, and strengthen new or developing systems.
Background
Coverage decisions for health technologies are increas-
ingly incorporating evidence-based approaches [1,2].
While the post-marketing evaluation of health technolo-
gies was initially motivated by goals such as timely access
to appropriate new technologies and the efficient alloca-
tion of finite resources [1], the move towards a more
systematic implementation of evidence-based approaches
has been advanced by increasing financial constraints and
a general focus on the scientific basis of decision-making
in healthcare [1,2].
Most formally established decision structures that rely on
evidence concern the reimbursement and pricing of phar-
maceuticals [2]. These were introduced as a way to obtain
value for money in addition to existing measures of cost
control targeting pharmaceutical expenditure. According to
the Organisation for Economic Co-operation and Develop-
ment, outpatient pharmaceutical expenditure alone was the
third largest item within total health expenditures among
its member countries in 2011 [3]. In the European Union
(EU), cost-containment measures include external and in-
ternal reference pricing, regulatory steering of market ac-
cess, public tendering, price freezes, cuts and discounts,
regulation of profit margins for pharmacists and whole-
salers, patient cost-sharing, guidelines for and monitoring
of prescribing behaviours, and generic substitution [4,5].
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Post-marketing evaluations of pharmaceuticals can
vary with regard to scope and methodology depending
on their exact purpose and the health system in which
they take place [6,7]. In Europe, health technology as-
sessment has been increasingly implemented in this con-
text since the beginning of the 2000s [5]. For the
purpose of this paper, we use the term ‘health technol-
ogy assessment’ (HTA) to describe scientifically sound
and transparently produced evidence syntheses which
cover a variable range of evidence domains and aim to
inform coverage decision-makers; we understand ‘rela-
tive effectiveness’ as “the extent to which an intervention
does more good than harm compared with one or more
intervention alternatives for achieving the desired results
when provided under the usual circumstances of health-
care practice” [1].
Pharmaceutical pricing and reimbursement modalities
in different countries have been the subject of an in-
creasing volume of comparative research in recent years
(an overview of relevant comparative publications can be
found in Additional file 1). While work on the under-
lying decision-making processes has been variable in re-
gional and thematic focus as well as methodological
approach, it has consistently found that evidence re-
quirements [8-11], as well as the characteristics of the
evaluation process [12,13], show similarities but also im-
portant differences across contexts; the same is true for
the number of stakeholders involved in evidence-based
coverage decisions and their interactions [14-16].
An overarching goal of the aforementioned research has
been the consideration and evaluation of current ap-
proaches towards evidence-based coverage decisions to
inform best practice. Recognizing that the analysis of
coverage decision-making is complicated in nature [17]
and requires, as a first step, a clear identification of stake-
holders involved, this paper aims to build on previous in-
sights and provide decision-makers and researchers with
an updated, concise overview of processes and responsibil-
ities in a broad range of European countries (n = 36). Fur-
thermore, it aims to illustrate differing approaches and
consider national and supranational possibilities for best
practice. As a secondary objective, the paper also set out
to assess the extent to which publicly available informa-




The landscape of coverage decision-making encompasses
a multitude of stakeholders and dynamics [17]. This work
focused on active regulatory institutions charged with the
evaluation of and/or decision-making on the value of
pharmaceuticals for public reimbursement or pricing in
EU Member States, candidate countries, and the European
Free Trade Association countries. Processes at regional
level were not specifically targeted in countries with
decentralized systems, with the exception of the United
Kingdom, where the systems for England and Wales, and
Scotland were studied separately. While the exact
definition of value may vary across systems and coun-
tries, benefit (in terms of patient health gain) is the
main element of interest, while costs (in terms of
lower out-of-pocket payments or improved efficiency
in the system) can be another key consideration
[18,19].
We used the analytical frameworks proposed by Hutton
et al. [2] and Rogowski et al. [20] to develop an informa-
tion collection tool tailored to our research objectives
(Table 1). Hutton et al. [2] proposed a two-level frame-
work, distinguishing between the ‘policy implementation
level’ of post-licensing evaluations overall and the ‘individ-
ual technology decision level’, which examines decision-
making processes for individual technologies. Rogowski et
al. [20] allow for seven building blocks in the analysis of
coverage decisions (trigger, participation, assessment,
appraisal, reimbursement, publication, management).
The concept behind our work is illustrated by the
shaded area in Figure 1. Figure 1 provides a simpli-
fied depiction of decision-making pathways for phar-
maceuticals from marketing authorization to patient
access, distinguishing between countries where phar-
maceuticals are evaluated for reimbursement based on
a price set in advance and countries where price and
reimbursement are determined once the evaluation
has been completed [21] (see also a similar distinction
by Towse and Barnsley [18]).
Table 1 Elements of information extraction tool on country processes
Decision-making on the value of pharmaceuticals
 Responsible Institution/Body
 Application area (remit)
 Evidence assessment
✠ production of evidence report
✠ assessment of evidence report
✠ assessment staff
 Evidence appraisal
✠ voting body and members
✠ term of office
 Re-Assessment
✠ Regular versus ad hoc
✠ Initiation (who/why)
Decision making on reimbursement and pricing of pharmaceuticals
 Responsible Institution / Body
 Restrictions
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Data collection
Our approach followed three distinct steps: (1) relevant
institutions were identified for each country, (2) infor-
mation was extracted from online sources, and (3) col-
lected information was sent to the identified institutions
for validation.
To identify relevant institutions, we searched for infor-
mation on the websites of international organisations
(European Network for Health Technology Assessment
(EUnetHTA), European Observatory on Health Systems
and Policies, International Society for Pharmacoeconomics
and Outcomes Research (ISPOR), WHO Collaborating
Centre for Pharmaceutical Pricing and Reimbursement)
and all related national ministries. Information was supple-
mented by a PubMed search for relevant literature (see
Additional file 2 for search strategy) which served as a
cross-check to ensure that information was complete and
well-founded.
Once the relevant institutions in each country had
been identified, information on processes and institu-
tional requirements related to evidence-based decision
making was collected using online sources. Institutional
websites were searched in a structured manner using the
site map and search functions (where available) as well as
linked material. Google Translate was used to extract infor-
mation from websites where no information was available
in one of the working languages (English, French, German,
Greek, and Russian). The plausibility of resulting interpre-
tations was checked by two investigators in each case. Syn-
thesised information on each country was used to create
individual country profiles. The structured search for infor-
mation took place in summer 2012 and was repeated in
February 2015 to ensure validity of information. Additional
file 3 provides a list of visited links per country.
After the initial search, all institutions included in the
analysis were contacted through email to verify the output
Figure 1 Evaluation of newly authorized pharmaceuticals for the purpose of reimbursement and pricing
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using the contact information provided by each website
(with up to five periodic reminders for non-respondents).
Results
An overview of information on all included countries
corresponding to the elements in Table 1 is presented in
Additional file 4: Table S1. Bolded country names cor-
respond to those cases where Google Translate had to
be used to extract information.
Institutions included in analysis and information
availability
Institutions in charge of decision-making on reimburse-
ment and pricing of pharmaceuticals were identified in
34 out of 36 countries included in the initial pool. In
Liechtenstein and Macedonia, there is no separate in-
stitution tasked with these decisions. Liechtenstein
generally adopts Switzerland’s positive list (Arznei- und
Spezialitätenliste) and in Macedonia ad hoc committees
are summoned by the Ministry of Health.
The type and extent of information available both on the
evaluation of relative effectiveness and on decision-making
for pharmaceutical coverage varies. For instance, informa-
tion is generally sparse (e.g. Greece, Luxembourg) or in-
complete (e.g. Czech Republic, Ireland, Iceland, Norway,
Poland, Turkey). Unfortunately, despite repeated attempts
to obtain verification of the information by country experts,
few responses were forthcoming (Czech Republic, Hungary,
Liechtenstein, Malta, Norway, Republic of Serbia); conse-
quently, no contact was attempted after the update search
in February 2015. In most cases, contacted institutions pro-
vided additional details or suggested rephrasing; one insti-
tution confirmed that information was complete and
accurate (Liechtenstein).
Decision-makers responsible for pharmaceutical coverage
Central processes to determine whether pharmaceuticals
are to be reimbursed and to set their price are initiated
after marketing authorization has been granted. Different
public regulatory bodies are involved across Europe, in-
cluding Ministries of Health/Social Affairs, Social Health
Insurance Organisations, National Health Service Execu-
tives, or Medicines Agencies.
In some countries, the same agencies are also in
charge of pharmaceutical marketing authorisation (e.g.
Denmark, Greece, Iceland, Italy). Similarly, while in
many countries the same regulatory institutions are re-
sponsible for the final political decision on a pharmaceu-
tical’s price and reimbursement status, in others, final
approval by a different instance is required (e.g. Belgium,
France, United Kingdom, Malta, the Netherlands, Portugal,
Republic of Serbia, Turkey).
Special groups within or independent public bodies
commissioned by the aforementioned institutions are
responsible for the assessment of the pharmaceutical’s
relative effectiveness. These committees or institutions
have been established in almost all European countries
included in the analysis. In Greece, pharmaceuticals are
included in the positive list, if they have undergone af-
firmative assessment in other EU countries. The positive
list was reinstated in 2011 amidst the financial crisis.
Remit of coverage decision-makers
Evaluation is mostly carried out for newly authorised
pharmaceuticals with new substances either exclusively
for the out-patient sector (n = 11) or for both the out-
and in-patient sectors. In a range of countries, already
reimbursed medicines are reassessed (see related section
below). Approximately half of the institutions studied
are also directly involved in price determination.
The assessment process
Assessments of the (relative) effectiveness of pharmaceuti-
cals are performed either by a separate committee within
the institution itself or a commissioned institution. In all
countries, manufacturers are required to submit evidence-
based applications, which are used as one of the main
sources of information for the assessment. In specific cases,
the evaluation committees or the commissioned institu-
tions (additionally) produce evidence reports themselves
(e.g. France, Sweden, United Kingdom–England and
Wales). Assessment groups consist of five to thirty mem-
bers, comprising scientists from different disciplines
including pharmacologists, pharmacists, epidemiologists,
physicians, economists, mathematicians, and statisticians.
The criteria underpinning the evaluation of pharma-
ceuticals for reimbursement and pricing decisions are
based on national legislation. One important criterion in
all countries is the assessment of (relative) effectiveness.
Costs also seem to play a significant role in all countries
where information on the issue was available (see Add-
itional file 4: Table S1), although they are often (n = 15)
considered on a case-by-case basis.
As a rule, the assessment staff receives submissions from
manufacturers, assesses the submitted material based on
clinical and/or economic criteria, completes or produces
evidence reports where required, and finally composes
conclusions or recommendations on the pharmaceutical’s
relative effectiveness. However, evidence requirements and
the degree of public availability of submitted material vary
from country to country.
The appraisal process
European countries keep the process of assessment of sci-
entific evidence structurally separate from its appraisal
and from final decision-making on reimbursement status,
reimbursement level, or price. Reimbursement or pricing
committees or institutions discuss the results of the
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completed reports provided by assessment groups in con-
text and formulate conclusions and give advice to the final
decision-makers or act as final decision-makers them-
selves (see Additional file 4: Table S1).
In most cases, assessment groups and reimbursement/
pricing committees represent the same body but differ in
composition. While assessment staff commonly consists
of scientists, a reimbursement/pricing committee add-
itionally includes representatives of ministries, healthcare
provider organisations (e.g. physicians and pharmacists),
health insurers, and representatives of patient groups. In
some countries, representatives of the pharmaceutical in-
dustry are also involved. However, their role in the process
varies: while in Belgium, France, Romania, and England
and Wales industry representatives act only as non-voting
participants in the committee, in other countries (e.g.
Switzerland, Turkey, United Kingdom–Scotland) they are
full members. The committees may additionally consult
external experts.
The terms of office of pricing/reimbursement committee
members range from 1 to 8 years. Discussion and appraisal
usually take place in closed sessions but the minutes of
these sessions are made publicly available in the majority
of countries for which information was available (except in
Estonia, Spain, Macedonia, Montenegro, Portugal, Turkey).
Outcomes of appraisal and reimbursement restrictions
Reimbursement levels can depend on product specifica-
tions, on the medical condition (indication), or on the
patient or population group. There can also be limita-
tions on the quantity of prescribed medicines, or restric-
tions regarding prescribers, on specific physicians and/or
medical institutions or treatment.
Re-evaluation of pharmaceuticals
Reviews of previous reimbursement or pricing decisions
can be substance-specific and occur on request of manu-
facturers or by initiative of the reimbursement/pricing in-
stitution or commission. They can be triggered by new
pharmacological, medical-therapeutic, or health-economic
evidence, or because of changes in indication or price
(Additional file 4: Table S1). Re-evaluations can also be
initiated by ministries or at the request of representatives
of interested parties such as patients, third party payers,
physicians, scientists, etc. In some countries (e.g. Belgium,
Finland), a regular review of coverage decisions on new
pharmaceuticals is scheduled every 1–5 years. In others,
the entire range of reimbursed pharmaceuticals is subject
to a regular review every 4–5 years (e.g. Spain, the
Netherlands).
Transparency of process of assessment and decision-making
The structured search identified gaps in information on
several dimensions of the assessment and decision-making
process for reimbursement and pricing of pharmaceuticals
in many of the 36 countries analysed, as indicated by miss-
ing information in Additional file 4: Table S1. Moreover,
available information often required considerable effort to
identify and was sometimes only included in legal acts or
regulatory documents. This was interpreted as a general
lack of accessibility to information and therefore transpar-
ency in many cases.
Discussion
Our findings confirm previous research indicating that
evidence-based decision-making processes for reim-
bursement and pricing of pharmaceuticals in Europe
demonstrate a number of similarities even in fundamen-
tally different healthcare systems. Thus, manufacturer
applications including relevant scientific evidence are al-
ways required for a pharmaceutical to be (re)considered
for coverage and build the basis of the evidence report
guiding decisions. The assessment and appraisal of the
evidence is kept structurally separate, even when carried
out within the same institution. Both assessment and ap-
praisal groups are multidisciplinary in nature but differ
in constitution: the former include primarily scientists
and methods experts while the latter tend to incorporate a
multitude of stakeholders such as third party payers and
occasionally patient or industry representatives (for more
detail on commission composition see also [16]).
Despite the similarities discussed above, no two sys-
tems are identical in terms of procedure or content of
evidence considered. This has also been discussed by
Allen et al. [15], who systematized HTA-related pro-
cesses in Europe into 10 archetypes and found that the
set-up of HTA systems was not connected to a country’s
geographical location or ability to pay. Taking into ac-
count our findings on the variability of HTA processes
and the lack of apparent clustering, one could assume -
as Allen et al. [15] did - that the historical development
of the legal and regulatory framework of the health sys-
tem as well political aspects can lead to the differences
observed in evidence-based decision-making processes.
Furthermore, it is likely that elements from country
models already in place informed the development of
newer systems, thus contributing to observed similarities.
The assessment of scientific evidence is kept separate
from contextualized appraisals and has been found to
show important similarities across European countries
[9]. Collaboration platforms exist both at European
(EUnetHTA) and international levels (International Net-
work of Agencies for Health Technology Assessment
(INAHTA), Health Technology Assessment International
(HTAi)). The collaboration of institutions involved in
HTA at the national level has further been endorsed by
the European Commission in its Directive on the appli-
cation of patients’ rights in cross-border healthcare, to
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be facilitated by EUnetHTA (Directive 2011/24/EU). The
Directive recognizes the importance of information
exchange in providing safe and appropriate technolo-
gies for patients in an overarching way. One of the
main aims of EUnetHTA since its inception in 2007
has been to facilitate the prevention of duplication of
efforts [22]. In addition to facilitating best practice,
information exchange may also be cost-effective in its
own right [23].
Coverage decisions, on the other hand, are taken at na-
tional (or regional) level. Perhaps as contributing factors
to this fact, substantial differences in the organization and
processes of decision-making institutions as well as in the
spectrum of possible decision outcomes can be observed.
However, communication platforms and the possibility for
knowledge exchange can be important for countries where
pathways for evidence-based decision-making are still be-
ing developed or difficult to introduce. While HTA may
be a uniquely appropriate approach for an efficient alloca-
tion of resources in constrained systems, the necessary
legal and organizational structures are not easy to estab-
lish [24]. Greece, for example, only introduced HTA as a
criterion for coverage in light of the financial crisis and
only considers pharmaceuticals for reimbursement if they
have been favourably evaluated in other countries [25].
Liechtenstein has traditionally been adopting decisions
made in the Swiss system. It could therefore be beneficial
for appraisal committees to have a platform enabling
structured dialogue, for example on the validity, appropri-
ateness and adaptability of evidence reports produced for
different contexts. Such a platform could furthermore fa-
cilitate discussion on the implementation of reimburse-
ment restrictions, which differ across countries in terms
of both rationale and frequency of application [26].
The lack of transparency observed in many cases may
pose an obstacle to cross-national collaboration. One of
the aims of this work was to explore publicly available in-
formation which was found to be fragmented or lacking
and difficult to obtain for many countries and for several
elements of the process such as the appointment and term
of appraisal committee members or the process of re-
evaluation. This has also been observed in previous
comparative research [12,14,16]. While the impact of
transparency on the reasonableness of decisions is con-
tested [27] it is clear that it remains paramount in regard
to accountability, consistency of implementation, and the
right to information of a broad range of stakeholders, not
least patients. Given the role of manufacturer submissions
outlined above, an important point to consider at this
juncture is that of ‘commercial in confidence’ information.
The extent to which such data is accepted by regulatory
institutions varies [28]. In the interest of transparency, in-
stitutional policies on the consideration of confidential in-
formation should be clearly stated.
Stakeholder participation and thorough evidence as-
sessment have been found to be of particular importance
for the scientific rigor and reasonableness of coverage
decisions [29]. Stakeholder participation is particularly
diverse across systems and an overall pattern is difficult
to distinguish. While most countries included in our
study provide explicit requirements on which manufac-
turer submissions should be based, these vary in terms
of content and comprehensiveness. Despite the similar-
ities observed in scientific approaches within coverage
decision-making systems [9], there seems to be a wide
variation in the thoroughness of process for evidence as-
sessment and appraisal. Building on previous initiatives
such as the HTAi Policy Forum [1], international dia-
logue among expert stakeholders can contribute to over-
coming methodological or procedural challenges.
Our work is not without limitations. As per the re-
search objectives, online sources were used to obtain in-
formation. Thus, any facet of the process not illustrated
in these sources was left out. Furthermore, the use of
Google Translate comes with its own validity con-
straints. While all efforts were made to check rendered
content, the possibility of misinterpretation cannot be
unequivocally excluded. Finally, normative statements
made in the available documentation were taken at face
value and were not compared to actual cases of coverage
decision-making.
The focus of this work was on the reimbursement and
pricing of pharmaceuticals. However, many countries are
expanding the range of technologies undergoing evidence-
based assessments to include medical devices, procedures,
and public health interventions. It is important to note
that reimbursement and pricing systems for other tech-
nologies, such as medical devices, differ considerably from
those described here [30]. Evidence-based decisions for
such technologies can thus be additionally complicated by
contextual factors such as less confluent marketing
authorization processes or concrete definition systems.
Finally, the type and composition of actors with final
decision-making power in matters of coverage and the
criteria they employ have not been explored in a compre-
hensive way and were not covered in detail in our work.
Future comparative analyses could aim to expand existing
knowledge and bring clarity to the issue.
Conclusions
Different public regulatory bodies are involved in pharma-
ceutical coverage decisions across Europe. The assessment
and appraisal of evidence is kept structurally separate and
based on material submitted by manufacturers. Reassess-
ment policies and reimbursement restrictions vary consid-
erably and transparency of process is limited in many
cases. International collaboration among HTA and regula-
tory bodies can promote knowledge exchange and
Panteli et al. Health Research Policy and Systems  (2015) 13:39 Page 6 of 8
efficiency of information production. It can thus help
refine existing approaches and improve evidence-based
coverage decision-making as well as prepare developing
systems for new challenges.
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